Becton, Dickinson and Company (BDX)
(Delayed Data from NYSE)
$233.25 USD
-3.09 (-1.31%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $233.15 -0.10 (-0.04%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$233.25 USD
-3.09 (-1.31%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $233.15 -0.10 (-0.04%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Zacks News
Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.
STERIS (STE) Buys Surgical Instrumentation Platform From BDX
by Zacks Equity Research
STERIS (STE) announces the buyout of surgical instrumentation assets from Becton, Dickinson and Company in a $540 million transaction.
BD's (BDX) Latest Product to Automate Clinical Flow Cytometry
by Zacks Equity Research
The latest worldwide commercial availability of BD's (BDX) product is expected to lead to increased automation in clinical lab workflow.
The Zacks Analyst Blog Highlights Apple, UnitedHealth, Eli Lilly, Walmart and Becton, Dickinson
by Zacks Equity Research
Apple, UnitedHealth, Eli Lilly, Walmart and Becton, Dickinson are part of the Zacks top Analyst Blog.
Top Stock Reports for Apple, UnitedHealth & Eli Lilly
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), UnitedHealth Group Incorporated (UNH) and Eli Lilly and Company (LLY).
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to a few regulatory approvals and product launches.
BD's (BDX) Latest Product Launch to Boost Research Outcome
by Zacks Equity Research
BD's (BDX) latest cell sorting technology is expected to speed up the process of cell sorting and allow researchers to answer complex biological questions.
BD's (BDX) New FDA Approval to Improve MRSA Diagnostics
by Zacks Equity Research
BD's (BDX) receipt of the latest FDA approval is likely to improve laboratory workflow.
BD (BDX) Q2 Earnings Surpass Estimates, FY23 View Revised
by Zacks Equity Research
BD's (BDX) overall top line benefits from revenue growth in the majority of its segments and both geographic regions in the fiscal second quarter.
Becton Dickinson (BDX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Becton Dickinson (BDX) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Becton Dickinson (BDX) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 4% and 3.48%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
BD (BDX) Gears Up for Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have benefited Q2 sales.
Here's Why You Should Retain Neogen (NEOG) Stock for Now
by Zacks Equity Research
Investors are optimistic about Neogen (NEOG) owing to strong performance across its Animal Safety and Food Safety segments.
Here's Why You Should Invest in Edwards Lifesciences (EW) Now
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences (EW) on the increased adoption of its premium RESILIA technologies.
Here's Why You Should Retain NextGen (NXGN) Stock for Now
by Zacks Equity Research
NextGen's (NXGN) strong product portfolio and continued demand for its solutions raise optimism about the stock.
Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Here's Why You Should Buy Boston Scientific (BSX) Stock
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) owing to impressive growth in MedSurg market share.
Abbott's (ABT) Q1 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Double-digit organic growth in Diabetes Care, Structural Heart, Heart Failure and Neuromodulation contributed to Abbott's (ABT) Q1 revenues.
Catalent (CTLT) Declines on Profit Warnings and CFO Exit
by Zacks Equity Research
Catalent (CTLT) issues a profit warning for third-quarter fiscal 2023 amid supply chain disruptions and operational challenges. It also announces the departure of its CFO.
Here's Why You Should Invest in Henry Schein (HSIC) Now
by Zacks Equity Research
Investors are optimistic about Henry Schein (HSIC), led by the strong potential in the company's dental technology joint venture, Henry Schein One.
Reasons to Retain Cardinal Health (CAH) in Your Portfolio
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.
Zacks.com featured highlights include Becton, Dickinson, Raytheon Technologies and Palantir Technologies
by Zacks Equity Research
Becton, Dickinson, Raytheon Technologies and Palantir Technologies are part of the Zacks Screen of the Week article.
BDX vs. WST: Which Stock Is the Better Value Option?
by Zacks Equity Research
BDX vs. WST: Which Stock Is the Better Value Option?
Merit Medical (MMSI) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about Merit Medical's (MMSI) strong product portfolio.
3 Stocks Worth a Buy for Solid Earnings Acceleration
by Tirthankar Chakraborty
Invest in stocks like Becton, Dickinson and Company (BDX), Raytheon Technologies (RTX) & Palantir Technologies (PLTR) as of now for superb earnings acceleration.
Masimo (MASI) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about Masimo's (MASI) slew of product launches.